Anika Therapeutics Inc. (NASDAQ:ANIK - Get Free Report) CEO Stephen Griffin acquired 12,200 shares of the stock in a transaction dated Thursday, April 30th. The stock was acquired at an average cost of $12.29 per share, for a total transaction of $149,938.00. Following the purchase, the chief executive officer directly owned 36,163 shares in the company, valued at approximately $444,443.27. The trade was a 50.91% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Anika Therapeutics Price Performance
Shares of ANIK opened at $12.45 on Friday. Anika Therapeutics Inc. has a one year low of $7.87 and a one year high of $16.24. The company has a 50-day moving average of $14.31 and a two-hundred day moving average of $11.29. The stock has a market cap of $166.84 million, a price-to-earnings ratio of -15.76 and a beta of 0.28.
Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $0.27 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.34. Anika Therapeutics had a negative net margin of 9.52% and a negative return on equity of 5.90%. The company had revenue of $29.61 million during the quarter, compared to analysts' expectations of $28.14 million. Analysts anticipate that Anika Therapeutics Inc. will post -0.61 earnings per share for the current year.
Trending Headlines about Anika Therapeutics
Here are the key news stories impacting Anika Therapeutics this week:
- Positive Sentiment: CEO insider purchase — CEO Stephen Griffin bought 12,200 shares at about $12.29, boosting his stake ~51%, a strong signal of management confidence that can support the stock. SEC Insider Filing
- Positive Sentiment: Q1 beat and operational improvement — ANIK reported Q1 EPS of $0.27 vs. a -$0.07 consensus and revenue $29.61M vs. $28.14M expected; gross margin rose to 64% and management delivered ~$4M of adjusted EBITDA, supporting a re‑rating on execution. Press Release / Slide Deck
- Positive Sentiment: Commercial momentum in core OA products — Company cites 13% total revenue growth, driven by Commercial channel strength (Monovisc, Orthovisc) and faster Integrity adoption, which investors view as recurring revenue drivers. Globe Newswire: Q1 Results
- Positive Sentiment: Analyst / bullish write‑up — A Seeking Alpha piece highlights upside as Integrity scales (510(k) cleared) and revenue momentum in 2025–2026, reinforcing the bullish narrative for investors focused on OA/regenerative growth. Bullish On Anika Therapeutics's Pullback As Integrity Scales
- Neutral Sentiment: FY2026 revenue guidance range—Company set revenue guidance of $114.0M–$122.5M vs. consensus ~$117.2M; range overlaps consensus, leaving guidance a neutral catalyst until more detailed modeling/quarterly cadence is confirmed. FY2026 Guidance (Slide Deck)
- Neutral Sentiment: Earnings call / transcripts available — Management commentary (call transcript and summaries) provide details on OEM timing, channel mix and cost actions; useful for re‑assessing margins and cadence but no new headline items beyond results. Q1 2026 Earnings Call Transcript
- Negative Sentiment: Regulatory and product timing risks — Growth opportunities (Hyalofast, Cingal) carry FDA timing/approval risk and the company remains broadly unprofitable on a net‑income/ROE basis historically, which could cap multiple expansion if approvals or adoption slow. Regulatory Risk Discussion
Analyst Upgrades and Downgrades
ANIK has been the subject of a number of research analyst reports. Barrington Research increased their target price on Anika Therapeutics from $16.00 to $17.00 and gave the company an "outperform" rating in a report on Friday, February 27th. Wall Street Zen upgraded Anika Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, March 7th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Anika Therapeutics currently has an average rating of "Hold" and an average target price of $17.00.
Get Our Latest Report on ANIK
Institutional Trading of Anika Therapeutics
Several institutional investors have recently made changes to their positions in ANIK. Opaleye Management Inc. boosted its holdings in shares of Anika Therapeutics by 49.1% during the second quarter. Opaleye Management Inc. now owns 588,797 shares of the biotechnology company's stock worth $6,229,000 after purchasing an additional 193,797 shares during the period. Capital Management Corp VA boosted its holdings in shares of Anika Therapeutics by 34.8% during the third quarter. Capital Management Corp VA now owns 551,248 shares of the biotechnology company's stock worth $5,182,000 after purchasing an additional 142,403 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Anika Therapeutics by 153.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 164,926 shares of the biotechnology company's stock worth $1,585,000 after purchasing an additional 99,951 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Anika Therapeutics by 78.1% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 195,585 shares of the biotechnology company's stock worth $1,880,000 after purchasing an additional 85,771 shares during the period. Finally, Jane Street Group LLC boosted its holdings in shares of Anika Therapeutics by 171.0% during the fourth quarter. Jane Street Group LLC now owns 134,768 shares of the biotechnology company's stock worth $1,295,000 after purchasing an additional 85,029 shares during the period. 91.53% of the stock is currently owned by institutional investors and hedge funds.
Anika Therapeutics Company Profile
(
Get Free Report)
Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika's proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.
The company's core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
